Promore Pharma: Improved numbers in Q4

The Q4 2018 financial results were somewhat better than we expected, as costs related to clinical trials decreased more than we had anticipated. Due to the delayed start of the PXL01 Phase 3 trial, we expect costs to remain at these lower levels throughout H1 2019, but to pick-up in H2. The recruitment of patients into the ongoing Phase 2b trial with LL-37 seem to proceed according to plan, enabling topline results in H1 2020..